DK3206692T3 - Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister - Google Patents

Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister Download PDF

Info

Publication number
DK3206692T3
DK3206692T3 DK15851238.4T DK15851238T DK3206692T3 DK 3206692 T3 DK3206692 T3 DK 3206692T3 DK 15851238 T DK15851238 T DK 15851238T DK 3206692 T3 DK3206692 T3 DK 3206692T3
Authority
DK
Denmark
Prior art keywords
glucocorticoid
treatment
receptor antagonists
liver disease
fatty liver
Prior art date
Application number
DK15851238.4T
Other languages
Danish (da)
English (en)
Inventor
Joseph K Belanoff
Hazel Hunt
Den Heuvel Jose Van
Onno C Meijer
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Application granted granted Critical
Publication of DK3206692T3 publication Critical patent/DK3206692T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15851238.4T 2014-10-15 2015-10-14 Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister DK3206692T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
DK3206692T3 true DK3206692T3 (da) 2024-04-29

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15851238.4T DK3206692T3 (da) 2014-10-15 2015-10-14 Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister

Country Status (22)

Country Link
US (5) US10238659B2 (enExample)
EP (2) EP4353310A3 (enExample)
JP (1) JP6761410B2 (enExample)
KR (1) KR102435956B1 (enExample)
CN (2) CN111557942B (enExample)
AU (1) AU2015333645B2 (enExample)
BR (1) BR112017007860B1 (enExample)
CA (1) CA2964625C (enExample)
DK (1) DK3206692T3 (enExample)
ES (1) ES2978871T3 (enExample)
FI (1) FI3206692T3 (enExample)
IL (1) IL251729B (enExample)
MX (1) MX2017004943A (enExample)
NZ (1) NZ731060A (enExample)
PH (1) PH12017500710B1 (enExample)
PL (1) PL3206692T3 (enExample)
PT (1) PT3206692T (enExample)
RU (1) RU2718921C2 (enExample)
SG (1) SG11201703024VA (enExample)
UA (1) UA123537C2 (enExample)
WO (1) WO2016061195A1 (enExample)
ZA (1) ZA201702813B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
KR102589213B1 (ko) * 2018-06-04 2023-10-12 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 사이클로헥세닐 글루코코르티코이드 수용체 조절제
US20220288091A1 (en) 2019-03-18 2022-09-15 Lynnette K. NIEMAN Method for Improving Insulin Sensitivity
BR112022022473A2 (pt) * 2020-05-06 2022-12-13 Corcept Therapeutics Inc Formulações de moduladores de receptor de glucocorticoide ciclo-hexil pirimidina
US11548856B2 (en) 2020-05-06 2023-01-10 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
IL303881A (en) * 2020-12-21 2023-08-01 Corcept Therapeutics Inc Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
EP4333848A4 (en) * 2021-05-05 2025-03-19 Corcept Therapeutics Incorporated Methods for reducing liver fat and treating fatty liver disease
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
EP1534273A4 (en) 2002-07-18 2007-08-22 Bristol Myers Squibb Co MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD
AU2006247537B2 (en) 2005-05-18 2011-01-06 Merck Sharp & Dohme Corp. D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
KR20080065617A (ko) * 2005-09-19 2008-07-14 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 글루코코티코이드 수용체 발현의 조절
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2008127591A2 (en) * 2007-04-13 2008-10-23 Schering Corporation Pyrimidinedione derivatives and use thereof
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
JP5511942B2 (ja) 2009-04-03 2014-06-04 エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト 組成物及びその使用
EP2685827B1 (en) 2011-03-18 2016-02-03 Corcept Therapeutics, Inc. Pyrimidine cyclohexyl glucocorticoid receptor modulators
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
BR112017007860B1 (pt) 2023-03-07
FI3206692T3 (fi) 2024-05-06
EP4353310A2 (en) 2024-04-17
JP2017531013A (ja) 2017-10-19
PH12017500710B1 (en) 2024-01-17
JP6761410B2 (ja) 2020-09-23
CN111557942A (zh) 2020-08-21
US10238659B2 (en) 2019-03-26
AU2015333645A1 (en) 2017-05-04
RU2017114596A3 (enExample) 2019-05-08
US20210085682A1 (en) 2021-03-25
WO2016061195A1 (en) 2016-04-21
SG11201703024VA (en) 2017-05-30
ES2978871T3 (es) 2024-09-23
CA2964625A1 (en) 2016-04-21
BR112017007860A2 (pt) 2018-01-16
EP3206692A1 (en) 2017-08-23
EP3206692A4 (en) 2018-05-30
RU2017114596A (ru) 2018-11-15
US11590135B2 (en) 2023-02-28
US12226417B2 (en) 2025-02-18
PL3206692T3 (pl) 2024-07-22
PH12017500710A1 (en) 2017-10-09
ZA201702813B (en) 2019-05-29
KR102435956B1 (ko) 2022-08-23
PT3206692T (pt) 2024-04-30
IL251729A0 (en) 2017-06-29
US20190151318A1 (en) 2019-05-23
CN111557942B (zh) 2023-10-03
AU2015333645B2 (en) 2020-01-30
KR20170066646A (ko) 2017-06-14
IL251729B (en) 2020-03-31
UA123537C2 (uk) 2021-04-21
CN107106562B (zh) 2020-08-18
RU2718921C2 (ru) 2020-04-15
EP4353310A3 (en) 2024-06-19
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
US20230218621A1 (en) 2023-07-13
MX2017004943A (es) 2017-07-19
CN107106562A (zh) 2017-08-29
NZ731060A (en) 2023-07-28
CA2964625C (en) 2023-03-07
US20160106749A1 (en) 2016-04-21
EP3206692B1 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
IL283761A (en) Compounds and methods for the targeted degradation of androgen receptor
DK3206692T3 (da) Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister
IL264607A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
IL262041A (en) Chimeric receptors and methods of use thereof
IL251970B (en) Anti-cd79b antibodies and methods of use
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
CL2016002462A1 (es) Anticuerpos anti-ox40 y métodos de uso
IL249092A0 (en) Anti-gitr antibodies and methods of use thereof
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
LT3653221T (lt) Anti-pvrig antikūnai ir naudojimo būdai
PT3548033T (pt) Compostos e respectivos métodos de utilização
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
IL251505A0 (en) Neuroactive compounds and methods of use thereof
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
BR112016020830A2 (pt) composição de poliolefina heterofásica modificada e método de preparação
PT3160964T (pt) Moduladores dos receptores de arilo e métodos de fabrico e utilização dos mesmos
BR112016006614A2 (pt) composições de trichoderma e métodos de uso
BR112016020889A2 (pt) variantes de hppd e métodos de uso
DK3280710T3 (da) Fremgangsmåde til fremstilling af androgenreceptorantagonister og mellemprodukter deraf
DK3166911T3 (da) Inkorporering af biologiske midler i gødning
DK3297653T3 (da) Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister
EP3398262A4 (en) MICRO-OUTER CHARACTERIZATION AND SELECTION
DK3250600T3 (da) Behandling af autoimmune lidelser med cd154-antistoffer